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Summary Serine proteases, such as a-chymotrypsin or elastase, caused an aggregation of rat ascites tumour
cell lines, AH-130, AH-109A and YS, in a protein free medium which preserved the cell viability. This
aggregation, which was monitored spectrophotometrically, was dependent upon the protease activities and was
resistant to treatment with either a calcium chelating reagent (EDTA) or neuraminidase. However, the tumour
cell aggregates were redispersed by treatment with deoxyribonuclease I (DNase I). This dispersal effect was
dependent upon the DNase activity. A possible relationship between the tumour cell aggregation and
development of blood-borne metastasis was studied. An intravenous inoculation in rats of tumour cell
aggregates preformed by the a-chymotrypsin treatment resulted in significantly higher numbers of lung
metastatic foci than an injection of single cells. When the re-separated single cells, prepared in vitro by
treatment with DNase I following a-chymotrypsin treatment, were injected instead of the aggregates, the
enhancement of metastasis was reversed. These enhancement and reversal effects were mimicked in vivo by
intravenous injections of protease and nuclease following inoculation of a single cell suspension. That is, the
number of metastatic foci caused by single cell inoculation followed by an intravenous a-chymotrypsin
injection, was higher than that in a control group receiving PBS instead of a-chymotrypsin. Again, this
augmentation was reversed by an injection of DNase I following a-chymotrypsin injection. Furthermore, an
injection of DNase I alone itself reduced the starting number of metastases resulting from injection of the
single tumour cell suspension. These data suggest that the metastatic behaviour of tumour cells may be
increased by protease inducible DNA dependent cell aggregation should it occur in the blood stream.
The metastasis of cancer cells is an important property
characterised by both the independent progression and the
degree of malignancy. In studies on the properties of tumour
cell lines with high and low metastatic potency, a positive
correlation between protease activities and the metastatic
potential of tumour cells has been demonstrated (Bosmann et
al., 1973; Liotta et al., 1980; Sloane et al., 1982; Wang et al.,
1980). It has also been shown that an important event in
blood-borne metastasis is the intercellular adhesion and ag-
gregation of circulating tumour cells (Nicolson & Winkel-
hake, 1975). The aggregated state of tumour cells in the
microcirculation may be favourable to lodgement in distant
organs. In this sense, the role of the plasma clotting system
(Kinjo, 1978) or platelets (Hara et al., 1980) in blood-borne
metastasis has been emphasised with special reference to the
formation of floating or plugged masses of tumour cells.
In our preliminary experiments, serine proteases such as
a-chymotrypsin or elastase caused an aggregation of rat
ascites tumour cell lines, AH-130, AH-109A and YS, without
any appreciable change in cell viability. In the present study,
we have examined a potential augmenting effect of protease-
induced cell aggregation in vitro and in vivo on blood-borne
metastasis using the lung-colonisation model with rat ascites
tumour cells. In addition, we also examined the effectiveness
of DNase I treatment (which prevented the protease-induced
cell aggregation) on blood-borne metastasis in the lung.
Materials and methods
Animals
Female Donryu rats weighing 130-180 g were generally used
in this study. These rats received a standard rat pellet diet
and tap water ad lib.
Reagents
Crystallised bovine pancreatic a-chymotrypsin, elastase, neur-
aminidase, bovine muscular actin, bovine pancreatic DNase I
and calf thymus DNA were purchased from Sigma Chemical
Co. (St Louis, MO, USA). Chymostatin and elastatinal were
purchased from Peptide Institute Inc. (Osaka, Japan). Hanks'
balanced salt solution (HBSS) (without phenol red) was pur-
chased from Nissui Pharm. Co. (Tokyo, Japan), HBSS (with-
out Ca2 , Mg2 + and phenol red) from Gibco (Grand Island,
NY, USA). An assay kit for lactate dehydrogenase (LDH)
was obtained from Shinotest Laboratories (Kanagawa,
Japan).
The DNase I was further purified using a high perform-
ance liquid chromatography system (LKB) with a TSK gel
3,000 SW gel permeation column (Tosoh). The final prepara-
tion was pure as judged by polyacrylamide gel electro-
phoresis in the presence of sodium dodecyl sulphate with or
without 1% P-mercaptoethanol.
Tumour cells
The rat ascites tumour cell lines used were AH-130, AH-
109A and YS. These tumour cell lines were supplied by the
Sasaki Institute, Tokyo, and were maintained by serial intra-
peritoneal transplantation into female Donryu rats. The
tumour cells were usually harvested 7 days after transplanta-
tion. The harvested tumour cells were washed three times
with HBSS by centrifugation at approximately 50-200g for
5 min at room temperature and, unless otherwise specified,
the cells were suspended in HBSS at a concentration of
1 x 107cells ml-'. The proportions of single cells in the
tumour cell suspensions of AH-130, AH-109A and YS were
around 50%, 95% and 100%, respectively. Most groups of
AH-130 cells comprised less than five cells.
Light microscopy
Light microscopic examination of tumour cells was made
without staining with an automatic microscope (Olympus,
New Vanox model AHBS). Tumour cell samples, with or
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without enzyme treatment, were fixed with 2% glutar-
aldehyde for 30 min at room temperature before the histo-
logical study was carried out.
Measurement ofcell viability
Viability of the tumour cells before and after enzyme treat-
ment was assessed in two different ways, the trypan blue dye
exclusion test and a measurement of LDH extracellular
leakage. LDH activity was assayed according to the method
of Cabaud and Wr6blewski (1958) using an assay kit.
Viability was expressed as a percentage of the LDH activity
extracted from the cells with 1% Triton X-100.
Enzyme assays
a-Chymotrypsin activity was assayed with N-benzyloxy-
carbonyl-L-tyrosine p-nitroanilide as the substrate by measur-
ing the initial velocity of continuous change of absorbence at
385 nm in 30 mM Tris-HCI (pH 8.0) containing 100 mM
CaC12 and 12% methanol at 37°C utilising a spectrophoto-
meter (Hitachi, Model 200-20). Elastase activity was assayed
in the same way as a-chymotrypsin but with N-acetyl-DL-
alanine-a-naphthyl ester (absorbence at 324 nm) as the subs-
trate. The DNase assay was carried out in 10 mM Tris-HC1
buffer containing 2 mM MgSO4 (pH 8.0) at 37°C using
50 fig m-' calf thymus DNA as the substrate. In this assay,
an increment of absorbence at 260 nm was continuously
measured using the spectrophotometer to obtain the initial
velocity of the reaction.
Tumour cell aggregometry
Tumour cell aggregation was assessed using an aggregometer
(Hema tracer 1, Niko Bioscience, Tokyo, Japan) originally
designed for measurement of platelet aggregation. In this
method, a change of light transmission of the tumour cell
suspension in a cuvette was continously monitored at 37°C
with constant stirring at 1,000 r.p.m. To calibrate this
apparatus, tumour cell suspensions with 4 x 106 cells ml'
and 2 x 106 cells ml-' were used instead of platelet rich
plasma and platelet poor plasma, respectively. Therefore, the
aggregometer was calibrated with the former and the latter
cell concentrations to express 0% and 100% optical transmis-
sion, respectively. Siliconised glass cuvettes were used in this
procedure. When the tumour cells clumped together, the
transmission of light at 660 nm increased. The tumour cell
suspension in the cuvette was stirred and various amounts of
the enzymes or the vehicle (PBS) were added to it. To
confirm the effect of the enzymes, several protease inhibitors
or other reagents were used to quench the aggregation-
promoting effect.
All reagents were dissolved in phosphate buffered saline
(PBS, pH 7.4), except for chymostatin in N,N'-diemthyl for-
mamide.
Generalprocedurefor study ofexperimental metastasis
Suspensions of the AH-109A or AH-130 cells in HBSS were
prepared with a viability of more than 97% as measured by
the trypan blue dye exclusion test. The cell inoculum in all
experiments was I x 106 per rat, injected intravenously into
the tail vein of Donryu rats. Rats were killed 12 days after
the tumour cell injection. Their lungs were intrabronchially
stained with Indian ink, then removed and fixed with
Fekete's solution which had been previously prepared by
mixing 100 ml of 70% ethanol, 10 ml of formaldehyde and
5 ml of glacial acetic acid. The number of metastatic foci on
the pleural surface was counted by the procedure described
by Wexler (1966). From the good correspondence between
the numbers of foci on the lung surface and on the cut
surface in several cases, we established that the foci number
on the surface was a good measure of the intensity of meta-
stasis in the whole lung.
Preparation ofaggregated and disaggregated tumour cell
suspensionsfor intravenous injection
The AH-130 and AH-109A aggregates were prepared by
treatment with a-chymotrypsin (1I00 Lg per 0.1 ml). Agg-
regates so prepared were disaggregated by a subsequent treat-
ment with DNase I (1.5 U per 0.1 ml). Prior to these various
treatments, the initial single cell suspensions had been equally
divided into two or three aliquots in order that injections
with cells in the aggregated and non-aggregated states comp-
rised the same total cell number.
Systemic treatment by intravenous enzyme injection
For in vivo experiments using protease, AH-109A cells were
initially injected into one tail vein and a-chymotrypsin solu-
tion (5 mg or 10 mg per 100 mg body weight of rat) was then
injected into the contralateral tail vein 3 min later. In the
control group, 0.1 ml of PBS was injected 3 min after the
tumour cell inoculation.
Statistical analysis
Differences in numbers of pulmonary metastases were com-
pared by the computerised, non-parametric, Mann-Whitney
U test.
Results
Enzyme-induced rat ascites tumour cell aggregation and
disaggregation
AH-109A tumour cell preparations consisted of about 95%
single cells, and no aggregates were observed even after
tumour cells were incubated with PBS (Figure la). In con-
trast, the AH-109A cells immediately aggregated when
treated with 100 tg ml-' a-chymotrypsin by gentle shaking at
room temperature. Figure lb shows a typical light micro-
scopic picture of the AH-109A tumour cell aggregates
induced by a-chymotrypsin treatment. It may be seen that
the aggregated sample consists of a large number of cell
clusters of various sizes and some remaining single cells.
Furthermore, the aggregates produced by a-chymotrypsin
treatment immediately dispersed when DNase I (1.5 Uml1')
was added to the cell suspension (Figure ic) as described in
detail below. Similar effects were also seen in AH-130 and
YS cell preparations.
Cell viability
The viability of the tumour cells used was more than 97% or
98% as determined by the trypan blue dye exclusion test or
the extracellular LDH assay, respectively. Table I shows the
extracellular LDH activity of the tumour cell suspensions
before and after the enzyme treatments which caused the cell
aggregation and disaggregation. No significant difference in
the extracellular LDH activity was observed, indicating that
the enzyme treatments did not influence the viability of
tumour cells.
Aggregometric studies on the mechanism oftumour cell
aggregation with serine protease
Addition of a-chymotrypsin or elastase to tumour cell
suspensions resulted in an increase in the light transmission
which reflected the cell aggregation. A typical pattern of
AH-130 tumour cell aggregation induced by the crystallised
a-chymotrypsin is demonstrated in Figure 2. As soon as
x-chymotrypsin was added to an AH-130 tumour cell suspen-
sion, the light transmission gradually increased and then
reached a plateau as shown in Figure 2 (trace A). Since the
extent of the transmission increment (delta transmission) in
each assay varied, probably due to some uncontrollable vari-
able, it was difficult to demonstrate the relationship betweenPROTEASES AND TUMOUR METASTASIS 609
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the extent of delta transmission and the enzymatic activity of
(x:,chymotrypsin. However, the time between protease addi-
tion and achievement of maximum transmission, followed by
a plateau (i.e. the aggregation period), was apparently related
to the concentration of (x-chymotrypsin added. In a typical
case, the aggregation periods were 0.46 and 1.8 min when
(x-chymotrypsin to produce final concentrations of 100 t*g
ml-' and jig ml-' respectively was added. The length of
the aggregation period was found to be inversely propor-
tional to the concentration of crystallised cE-chymotrypsin
added, for a given batch of the cell suspension (data not
shown). Aggregation was observed with a dose of a-chymo-
trypsin giving a final concentration as low as ;Lg ml -'.
When PBS (solv'ent of protease) was added instead of the
ot-chymo-trypsin solution to the cell suspensions, no aggrega-
tion was detected. A typical example for AH-1 30 tumour
cells is shown in Figure 2 (trace B).
Elastase also caused aggregation of AH-130 cells, and the
aggregometric pattern was quite similar to that produced by
a-chymotrypsin, although the effective concentrations of the
proteases were different. A minimum final concentration of
10 igml-' of elastase was required for AH-130 tumour cell
aggregation. In a typical experiment, the aggregation period
with 1001agml-' of elastase was 2.0min.
Suspensions of AH-109A or YS cells which contained the
same number of cells as the AH-130 cell suspension were also
aggregated when treated with the proteases as described
above, and the aggregometric patterns and dose-time rela-
tions were similar to those for AH-130.
The experiments were repeated at least three times for each
protease and each cell type. Using the conditions described in
Materials and methods, the results described above were
found to be reproducible.
Effect ofprotease inhibitors and other reagents including
DNase I on theprotease-induced tumour cell aggregation
To examine whether the aggregating effect of these proteases
was dependent upon the enzymatic activity of each protease,
a specific inhibitor for each protease, such as chymostatin for
a-chymotrypsin or elastatinal for elastase, was chosen. In the
esterolytic or amidolytic assay, chymostatin and elastatinal
inhibited only ax-chymotrypsin or elastase respectively, but
not the other protease.
The protease-induced tumour cell aggregation brought
about by 100 ltg ml-l 'x-chymotrypsin was inhibited by
chymostatin (2.5AM). Likewise, tumour cell aggregation
could not be brought about by 100jig ml-' of elastase in the
presence of elastatinal (25lsM). On the other hand, chymo-
statin did not inhibit the aggregation caused by elastase and
elastatinal did not inhibit a-chymotrypsin-induced tumour
cell aggregation. These results therefore indicate that the
serine protease-induced tumour cell aggregation may be attri-
buted to the enzymatic activity of each protease.
EDTA (5 and 10 mM), a calcium ion chelator which has
been reported to influence cell aggregation, did not inhibit
the tumour cell aggregation caused by a-chymotrypsin treat-
ment. Neuraminidase (10, 40 and 100j*g ml-'), a cleaver of
sialic acids in the cell surface, also did not influence the
tumour cell aggregation when present during incubation for
60, 100 and 200 min at 37C.
However, in the presence of DNase I, the tumour cell
aggregation caused by a-chymotrypsin treatment was com-
pletely prevented. Furthermore, addition of DNase I to ag-
gregated tumour cell suspensions produced by previous treat-
ment with a-chymotrypsin resulted in a decrease of the light
transmission which reflected the dissociation of the aggre-
gates within several seconds. In the 15 U ml-' to 150IsU
ml-' dose range, DNase I effectively dissociated the aggre-
gates previously formed with x-chymotrypsin (100t*g ml-').
To confirm the effect of DNase I, two different types of
inhibitor of DNase I, EDTA and actin, were used. Jn the
presence of 5 mM EDTA or actin (10 and 50,*gml-'), the
effect of DNase I on tumour cell aggregates was lost. Figure
3 shows typical patterns for the effects of chymostatin and
EDTA on tumour cell aggregation induced by ax-chymo-
trypsin, and of EDTA and actin on tumour cell disaggrega-
tion induced by DNase I.
From these results it may be concluded that the protease-
induced tumour cell aggregation was associated with a func-
tion of DNA.
Potential effects ofprotease-induced aggregation in metastasis
and its reversal with DNase I
To examine the influence of the protease-induced aggregation
upon tumour metastasis in vivo, two different types of experi-
ment were performed. In the first experiment, the tumour cell
aggregates were performed by treatment with the proteases
and thereafter intravenously injected into Donryu rats. In the
second experiment, the untreated tumour cells were intra-
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Table I Tumour cell viability before and after enzyme treatment as measured by
extracellular leakage of lactate dehydrogenase (LDH) activity
Before enzyme Afterprotease After DNase I Triton X-100
treatment treatment treatment treatment
Experiment WU v (%) WU v (%) WU v (%) WU v (%)
1 140 97.6 123 97.9 120 98.0 5900 0
2 80 98.1 75 98.2 69 98.4 4200 0
3 103 98.2 98 98.3 94 98.3 5600 0
v(%)
Mean ± s.d. 97.97 ± 0.32 98.13 ± 0.20 98.32 ± 0.21 0
Extracellular leakage of LDH activity was assayed as described in Materials and
methods. AH-109A tumour cells were suspended in HBSS at a concentration of4 x 106
cells m'-l. Before and after the treatment with 100 gig ml-
I ac-chymotrypsin or 1.5 U ml-
I
DNase I for 5 minatropmtemperature, LDHactivitywasmeasuredinsupernatantofthe
cell suspensions aftercentrifugation at 1,200 r.p.m. for 5 min. The activity was expressed
in the Wr6blewski unit (WU). Duplicate assay was performed for each sample and the
values shown are averages. Total LDH activity of cell suspensions was measured by a
methodinwhich tumourcell suspensions weretreatedwith 1% TritonX-100for60 minat
room temperature. After this treatment, the viability of tumour cell measured by the
trypan blue dye exclusion test was 0%. The cell viability in per cent (v (%)-, which was
calculated from the LDH activity, is also shown. Means and standard deviations ofthe
viabilities in the 3 experiments are shown on the bottom line. There are no statistically
significant differences before and after the enzyme treatments.
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Figure 2 Drawing of a typical aggregometric pattern of tumour
cells treated with a-chymotrypsin. 0% and 100% mean transmis-
sions at 660 nm were calibrated using cell suspensions with
4 x .106 and 2 x 106 cells m-', respectively. Arrows indicate the
time point when 201lI of the sample were added to 180 iLl of the
AH-130 tumour cell suspension (4 x 106 cells ml-'). A rapid in-
crement of the light transmission observed at this point was a
dilution effect. Trace A, addition ofa-chymotrypsin (100 gg ml-')
caused a gradual increase followed by a plateau in the transmis-
sion. The duration of the increase (shown by a double headed
arrow with a) designates the aggregation period. Trace B, addi-
tion of PBS as a negative control.
venously injected and the protease was then injected into the
contralateral tail vein in order to promote tumour cell ag-
gregation in the blood stream. In each type of experiment,
the effect of DNase I treatment following protease administ-
ration was also examined. YS tumour cells could not be used
in these experiments because of the high mortality of the
animals intravenously inoculated. The numbers ofpulmonary
metastatic foci were compared as described in Materials and
methods.
Inoculation oftumour cell aggregates preformed by the
protease treatment
In this experiment, AH-130 or AH-109A cells were treated in
vitro with a-chymotrypsin (100gig per 0.1 ml) in order to
produce aggregation. The results are summarised in Table II.
The groups receiving aggregated cells had more pulmonary
metastases than the groups receiving single cells. For exam-
ple, on the 12th day following AH-130 tumour cells, the
number of lung metastatic foci in the group with a-
chymotrypsin-induced aggregation was 71.10 ± 16.68, while
the number in the group receiving single cells and treated
with PBS was 42.40 ± 11.50. The difference between the
former and latter groups was statistically significant with
P<0.01.
Next, to make a striking contrast in the metastatic
experiments between aggregated cells and single cells, the
disaggregated AH-130 and AH-109A cells were prepared in
vitro by successive treatment with a-chymotrypsin (100gig per
0.1 ml) and DNase I (1.5 U per 0.1 ml), and then intra-
venously injected into the tail vein. Aggregated tumour cells
as the positive control were prepared by treatment with
a-chymotrypsin (100gg per 0.1 ml). The results are sum-
marised in Table III. The disaggregated single cell injection
group had statistically significantly fewer metastatic foci than
the aggregated cell injection group. The numbers of lung
metastatic foci in the disaggregated AH-130 or AH-109A cell
injection groups were 49.50 ± 18.98 or 20.50 ± 8.58, respec-
tively, and those in the original AH-130 or AH-109A single
cell injection groups were 39.00 ± 7.21 and 15.60 ± 6.64,
respectively. Despite the different treatments, no statistical
difference in the focus number was observed between the two
different types of single cell suspensions of AH-130 or AH-
109A cells. Therefore, the enhancing effect of the protease
treatment in vitro on the lung-colonising ability must have
been a result of tumour cell aggregation per se. The DNase I
treatment reversed both the aggregation and the increased
metastatic ability of the cells.
Effects ofprotease and nuclease treatments in vivo on tumour
cell metastasis
Untreated AH-109A cells were intravenously injected and
thereafter (3 min later) a-chymotrypsin (5 mg or 10mg per
100 g body weight of rat) was injected into tail vein to
promote cell aggregation in vivo. The amount of a-
chymotrypsin injected into the rat was determined by an
enzymatic assay in vitro for the a-chymotrypsin inhibitory
capacity of rat plasma. On the assumption that blood volume
is 1/13 of the body weight and haematocrit is 40%, a dose ofPROTEASES AND TUMOUR METASTASIS 611
5 mg a-chymotrypsin per 100 g body weight was the
minimum requirement to exceed the inhibitory capacity of
circulating blood. As shown in Table IV, the groups injected
with a-chymotrypsin (5 mg or 10 mg per 100 g body weight)
developed more pulmonary metastases (1.8 or 2.5 times more
foci, respectively) than the PBS injection group. The
differences in the focus number between the former two
groups and the latter were statistically significant with
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Table II Effect of protease-induced tumour cell aggregation on
pulmonary metastases in Donryu rats
Cell line and No. ofmetastaticfoci in the lung
treatment Mean ± s.d Range P
AH-130
a-chymotrypsin 71.10 ± 16.68 40-981 <001 PBS 42.40± 11.50 26-61 J
AH-109A
a-chymotrypsin 38.50 ± 16.08 13-66 <001 PaS 17.20± 8.30 4-30 J
Tumourcells(1 x 106)wereintravenously inoculated intothetailvein
of Donryu rats (n = 10 in each group). The aggregated cell groups
received an intravenous injection oftumour cell suspension pretreated
with a-chymotrypsin (100jig per 0.1 ml). The original single cell group
A was pretreated with PBS. On day 12 after inoculation, the metastatic
foci on the lung surface were counted.
P<0.01. These results indicated that the aggregation-
associated enhancement of blood-borne metastasis could also
be produced in vivo by systemic treatment with the protease.
B The reversing effect of DNase I in experiments with systemic
treatment was then examined. In this case, a-chymotrypsin
(5 mg per 100 g body weight) was injected 3 min after
tumour cell inoculation and DNase I (1.5 U per 0.1 ml) was
injected after a further 3 min. The effect of such systemic
DNase I treatment on the number of lung foci resulting from
injection of single tumour cells was also examined, i.e. un-
treated AH-109A cells were intravenously injected and, 3 min
later, DNase I (0.3 U per 0.1 ml) was injected into the con-
tralateral tail vein. As shown in Table V, the augmentation
of lung metastasis caused by the a-chymotrypsin injection
was reversed by the injection of DNase I following a-
chymotrypsin. In addition, injection of DNase I alone pro-
duced a 37% reduction in the number of metastatic foci as
compared with the PBS injected group. The difference in the
focus number was statistically significant (P<0.05). The
results therefore indicate that DNase I is able to reduce the
number of lung foci produced by intravenously injected
tumour cells.
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Figure 3 Effects of chymostatin and EDTA on AH-130 tumour
cell aggregation induced by a-chymotrypsin, and of EDTA and
actin on the tumour cell disaggregation induced by DNase I The
experimental conditions were basically the same as Figure 2.
Trace A, addition of a-chymotrypsin (arrow) did not cause
tumour cell aggregation in the presence of chymostatin (2.5fM).
Trace B, after treatment of the cells with EDTA (5 or 10 mM,
arrow with a) with addition of a-chymotrypsin (arrow with b)
still induced tumour cell aggregation to the same extent as the
positive control. Trace C, addition of DNase I (15 U ml-', arrow
c) to the cells pretreated and aggregated with a-chymotrypsin
(arrow a) immediately caused a decrease in light transmission
indicating the occurrence of disaggregation. Trace D, after treat-
ment with 5 mM EDTA or 10 jLg ml-' of actin (arrow b) of the
cell aggregates induced by a-chymotrypsin (arrow a), the addition
of DNase I (arrow c) did not cause the disaggregation.
The intravenous injection of protease-induced tumour cell
aggregates caused more pulmonary metastases than an equal
number of single cells. The higher metastatic potency was
reversed when the cell aggregates were redispersed into single
cells by treatment with DNase I. Therefore, it seems likely
that the aggregated state itself, rather than some other possi-
ble change caused by the protease treatment, is responsible
for the increased number of metastases. Emboli formation
has been postulated to be advantageous for circulating
tumour cells to arrest in distant organs and subsequently
develop into metastatic foci. Fidler (1973) originally demon-
strated the importance of cluster formation of circulating
tumour cells in metastasis using B16 melanoma cells in mice.
The results of the present experiments may relate to emboli
formation in the pulmonary circulation. Injection of single
cells followed by a-chymotrypsin was an attempt to promote
protease-induced tumour cell aggregation in the blood
stream. Although there is no evidence for the actual occur-
rence of such aggregation, the number of metastatic foci
which resulted was similar to that caused by the injection of
preformed aggregates. A dose of 5 mg per 100 g body weight
of a-chymotrypsin was the minimum requirement to exceed
the a-chymotrypsin neutralising capacity calculated for whole
blood. A lower dose of a-chymotrypsin (such as 100;lg per
100 g body weight) did not cause enhancement of metastasis
(data not shown). Therefore, it seems likely that the enhance-
ment of metastasis was due to the enzymatic activity of
a-chymotrypsin injected. The dose dependent enhancement of
the metastasis between 5 and 10 mg per 100 g body weight of
a-chymotrypsin also supports this concept. Although
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Table III Reversibility of the enhancing effect of protease-induced aggregation on
pulmonary metastases
Cell line and No. ofmetastaticfoci in the lung
treatment Mean ± s.d Range P
AH-130
a-chymotrypsin and DNase I 49.50 ± 18.98 28-98 <0.01
a-chymotrypsin 85.80 21.26 50-120 J 4 n.s.
PBS 39.00 7.21 28-50 J
AH-109A
a-chymotrypsin and DNase I 20.50 ± 8.58 5-32 <0.01
a-chymotrypsin 42.70 ± 13.47 20-64 J 4n.s.
PBS 15.60 6.64 6-26 )
Tumour cells (I x 106) were intravenously inoculated into the tail vein ofDonryu rats
(n = 10 in each group). The disaggregated cell group was successively treated with
a-chymotrypsin (100iLg per 0.1 ml) and DNase I (1.5 U per 0.1 ml). The aggregated cell
group was treated with a-chymotrypsin (100pAg per 0.1 ml). The original single cell group
was treated with PBS. On day 12, the metastatic foci on the lung surface were counted.
n.s. = no signficant difference.
Table IV Enhancement ofpulmonary metastases in single tumour cell
inoculated Donryu rats by systemic treatment with protease
No. ofmetastaticfoci in the lung
Experiments Mean ± s.d. Range P
PBS 13.40± 5.17 62~<o
a-chymotrypsin 10mg 33.50 ± 11.52 18-52) 1<0.01
5 mg 24.50 5.80 15-33
Untreated AH-109A tumour cells (I x 106) were intravenously
inoculated into thetailvein ofDonryu rats(n = 10 ineachgroup). Three
min later a-chymotrypsin (10 mg or 5 mg per 100 g body weight) was
injected into thecontralateral tail vein. 0.1 ml ofPBS wasinjected 3 min
after tumour cell inoculation in the control group. On day 12 after
inoculation, the metastatic foci on the lung surface were counted.
Table V Effects ofsystemic DNase I treatment in reducingpulmonary
metastases of rat ascites tumour cells
No. ofmetastaticfoci in the lung
Experiments Mean ± s.d. Range P
ax-chymotrypsin 39.50 11.54 23-58) <0.01
ax-chymotrypsin and DNase I 21.75 +8.89 8-34J
PBS 23.38 6.70 12-32 A
DNase I 14.75 6.34 2-22 J <0.0
Untreated AH-109A tumour cells (1 x 106) were intravenously
injected into a tail vein of Donryu rats (n = 8 in each group).
a-Chymotrypsin (5 mg per 100 g body weight) and DNase 1(1.5 U per
0.1 ml) were injected in thisorder at 3 min intervals after the tumourcell
inoculation. In the positive control group, a-chymotrypsin (5 mg per
100 g body weight) alone was injected 3 min after the tumour cell
inoculation. In another group, DNase 1 (0.3 U per 0.1 ml) was injected
alone into the other tail vein 3 min after the tumour cell inoculation. In
the control group, 0.1 ml of PBS was injected after the tumour cell
inoculation. On day 12 after inoculation, the metastatic foci on the lung
surface were counted.
systemic treatment with a-chymotrypsin was used in the pre-
sent model experiments, locally generated proteases in blood
vessels must be the real candidate agent causing unfavourable
tumour cell aggregation during clinical metastasis. The fact
that anti-inflammatory agents and neutral proteinase
inhibitors prevented pulmonary metastasis in mice bearing
Lewis lung carcinoma (Giraldi et al., 1980) would appear to
support our speculation.
In our in vitro experiments, aggregated cells were
redispersed by treatment with DNase, indicating that DNA
molecules must be essential for keeping the cells aggregated.
However, treatment of a single cell suspension with
exogenous thymic DNA did not cause cell aggregation (data
not shown). Therefore, the essential molecule is not DNA
alone but a complex between DNA and some other molecule.
The native of such a DNA complex is an interesting and
important question to be answered. There is a speculation
that nucleoprotein might be released from ruptured dead cells
by protease treatment (Steinberg, 1963), and Fidler (1970)
has emphasised an important role for dead tumour cells in
the formation of clinical metastases. In the present
experiments, however, no difference in the viability of tumour
cells was observed before and after the enzyme treatment, at
least as determined by the LDH assay or by the dye exclu-
sion test. Therefore, we did not obtain any evidence for the
speculation that the DNA complex is chromosomal in origin.
Alternatively, Rosenberg's group has pointed to the presence
of DNA on the cell surface and a correlation between the
amount of surface DNA and the metastatic potency of
tumour cell lines (Aggarwal et al., 1975). To examine this
possibility, we carried out an experiment in which the tumour
cells were initially treated with DNase I to hydrolyse any
such surface DNA. However, when these cells were treated
with x-chymotrypsin after extensive washing to remove
DNase I, the cells were able to aggregate to the same extent
as the DNase I untreated control cells (data not shown),
suggesting that the DNA complex is not simply present on
the cell surface. Hence, in order to reach conclusions about
the origin of the DNA involved in the tumour cell aggrega-
tion, as presented here, further detailed work is required in
future. Nevertheless, it is of interest that systemic DNase I
treatment reduced even the base-line level of pulmonary
metastases in the present study (Table V). There has been a
previous exciting report of reduction in leukaemic cell meta-
stasis in AKR mice treated with repetitive intraperitoneal
DNase injection (Salganik et al., 1967).
In the present study, we were not able to elucidate the
mechanism involved in the tumour cell aggregation brought
about by protease treatment. The proteases may modify
either the DNA complex (if it is a nucleoprotein) or protein
moieties on the tumour cell membrane. However, even in the
former case, the mechanism must be complicated, since the
DNA complex does not seem to be simply present on the cell
membrane.
In the literature, Weiss (1958) first reported that trypsin
induced Sarcoma 37 ascites cell aggregation over 30 years
ago. A similar phenomenon seems to have been observed in
the classical research in experimental embryology in the
1950s (Auerbach & Grobstein, 1958; Rinaldini, 1958; Mos-
cona, 1961; Steinberg, 1963). Auerbach and Grobstein (1958)
reported the appearance of 'gummy material' which trapped
single cells and small cell masses when they attempted to
prepare free cells from kidney rudiment by treatment with
trypsin or chymotrypsin. They also mentioned that these
aggregates disappeared in a crude DNase solution. These
phenomena, observed by the ontogenists and ourselves,
might therefore be caused by a similar mechanism.
The authors are grateful to Dr Ishimaru of the Department of
Pathology, Kumamoto University Medical School Hospital, for sup-
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